Clarivate Forecasts 10%-15% Free Cash Flow Growth by 2027 Following Life Sciences & Healthcare Divestiture
Clarivate (CLVT) has reached a significant milestone in its corporate transformation following the early completion of the strategic sale of its Life Sciences & Healthcare segment. This divestiture is a central component of the company's long-term restructuring strategy. As a result of this reorganization, management anticipates that the company will achieve free cash flow growth in the range of 10% to 15% by 2027. The move aims to streamline operations and focus resources on core business segments.
Tickers: $CLVT
Topics: earnings call life sciences segment divestiture strategic sale
Read the full article at Seeking Alpha
Part of the story Cogent Communications Reports Q3 2026 Results with Improved EBITDA Margins and Wavelength Growth (22 articles)